Caribou Biosciences doses first patient in CaMMouflage Phase 1 trial of CB-011

Caribou Biosciences announced the first patient has been dosed with CB-011 at dose level 1 in the CaMMouflage Phase 1 trial for adults with relapsed or refractory multiple myeloma. CB-011 is an allogeneic anti-BCMA CAR-T cell therapy designed to improve antitumor activity by reducing T and natural killer cell-mediated rejection. CB-011 is the first allogeneic CAR-T cell therapy, to Caribou’s knowledge, with an immune cloaking approach that includes both removal of the endogenous beta-2 microglobulin protein and insertion of a B2M-human-leukocyte-antigen-E-peptide transgene. This strategy has the potential to improve the antitumor activity by blunting CAR-T cell rejection mediated by both the patient’s T cells and NK cells. Caribou plans to continue to enroll additional patients at dose level 1 in the CaMMouflage trial and provide an update on the clearance of dose levels as appropriate.